Amanta Healthcare IPO details
Amanta Healthcare IPO is a book-built issue of 1.00 crore equity shares, entirely a fresh issue. The IPO opens on September 1, 2025 and closes on September 3, 2025. Basis of allotment is scheduled for September 4, 2025 and the shares are proposed to list on both BSE and NSE on September 8, 2025. The price band is Rs. 120-126 and lot size is 119 shares. Beeline Capital Advisors Pvt. Ltd. is the book running lead manager to the issue, while MUFG Intime India Pvt. Ltd. is acting as the registrar.
Table of Contents
Amanta Healthcare IPO latest updates
Grey market premium for this IPO is expected to start soon
Amanta Healthcare IPO Key Dates
| Anchor portion | |
| IPO opens on | 1 September 2025 |
| IPO Closes on | 3 September 2025 |
| IPO Allotment on | 4 September 2025 |
| Unblocking of Asba | 5 September 2025 |
| Credit of Shares | 5 September 2025 |
| Listing of Shares | 8 September 2025 |
Who are the promoters of Amanta Healthcare IPO?
The promoters of the Company are Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendra Kumar Patel and Milcent Appliances Private Limited.
The promoters hold 85.60% shares in the pre IPO capital of the company.
What are the Objects of Amanta Healthcare IPO?
The Offer comprises a Fresh Issue by the Company.
The net proceeds of the Offer are proposed to be utilised in the following manner:
+Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat. Rs. 70 Crore
+Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat Rs. 30.13 Crore
+General Corporate Purposes
What is the business of Amanta Healthcare?
Amanta Healthcare IPO Details
| IPO opens on | 1 September, 2025 |
| IPO closes on | 3 September, 2025 |
| Issue Type | Book Built Issue IPO |
| Issue Size | 100,20,000 Shares / Rs ? Crore |
| * Fresh Issue | |
| * Offer for Sale | |
| Face Value per share: | Rs. 10 |
| Price Band | Rs. |
| Retail Discount | Rs 0 per share |
| Employee discount | Rs. – per share |
| Retail Lot Size | Shares |
| Listing will at | BSE, NSE |
How are the shares offered in Amanta Healthcare IPO?
| Investor Category | Shares Offered |
| QIB Shares Offered | Not more than 50.00% of the Net Issue |
| Retail Shares Offered | Not less than 35.00% of the Net Issue |
| NII Shares Offered | Not less than 15.00% of the Net Issue |
How can the shares be applied in Amanta Healthcare IPO?
| Application | Lots | Shares | Amount Rs. |
| Retail (Min) | 1 | 119 | 14,994 |
| Retail (Max) | 13 | 1,547 | 1,94,922 |
| S-HNI (Min) | 14 | 1,666 | 2,09,916 |
| S-HNI (Max) | 66 | 7,854 | 9,89,604 |
| B-HNI (Min) | 67 | 7,973 | 10,04,598 |
Amanta Healthcare IPO allotment Status
Allotment of this IPO will be announced on XXX
| Registered Office of the company Amanta Healthcare Ltd. 8th Floor, Shaligram Corporates C.J. Marg Ambli, Ahmedabad, Gujarat, 380058 |
|
| Who are the Lead Managers of Amanta Healthcare IPO? Beeline Capital Advisors Pvt ltd |
|
| Registrar to IPO | |
| Mufg Intime India Pvt Limited |
Amanta Healthcare IPO Financial Snapshot
| Period Ended | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
| Assets | 381.76 | 352.12 | 374.06 |
| Total Income | 276.09 | 281.61 | 262.7 |
| Profit After Tax | 10.5 | 3.63 | -2.11 |
| EBITDA | 61.05 | 58.76 | 56.31 |
| Net Worth | 96.39 | 66.29 | 62.88 |
| Reserves and Surplus | 67.56 | 39.46 | 36.05 |
| Total Borrowing | 195 | 205.23 | 215.66 |
| Amount in ₹ Crore | |||
Key Performance Indicators
| KPI | Values |
| ROE | 12.42% |
| ROCE | 13.72% |
| Debt/Equity | 2.02 |
| RoNW | 10.89% |
| PAT Margin | 3.86% |
| EBITDA Margin | 22.11% |
| EPS | 3.64 |
| PER | 34.59 |
How Amanta Healthcare IPO compares with the Peers?
Peer Comparison.
| Company Name | P/E (x) | RoNW (%) |
| Amanta Healthcare Limited | 34.59 | 10.89 |
| Denis Chem Lab Ltd | 15.92 | 9.49 |
Amanta Healthcare IPO Condensed Review by Paresh Gordhandas, CA & Research Analyst
At the upper band of Rs. 126, Amanta Healthcare commands a P/E multiple of ~35x FY25 earnings. While valuations appear slightly on the higher side compared to some listed SME peers, the stable revenue base, rising margins, and sectoral demand visibility in healthcare justify a premium.
👉 Chanakya Verdict: Investors with long-term outlook may subscribe. Short-term listing gains may depend on market sentiment.
Amanta Healthcare is a pharmaceutical company specializing in sterile liquid formulations such as IV fluids, diluents, ophthalmic solutions, respiratory care products, and medical devices. It markets over 45 generic products in India and exports to more than 20 countries.
The IPO opens for subscription on September 1, 2025 and closes on September 3, 2025. Basis of allotment is scheduled for September 4, 2025, and listing on BSE & NSE is expected on September 8, 2025.
Price Band: Rs. 120–126 per share
Lot Size: 119 shares
Minimum Investment: Rs. 14,994 (upper price band)
The company posted Total Income of Rs. 276.09 crore and PAT of Rs. 10.5 crore in FY25, a significant improvement from Rs. 3.63 crore in FY24 and a loss in FY23. EBITDA margins are strong at ~22%. Borrowings reduced from Rs. 215.66 crore (FY23) to Rs. 195 crore (FY25).
Yes, investors may consider subscribing, given the improved profitability, strong EBITDA margins, and defensive healthcare sector positioning. The issue is suitable for medium to long-term investors, though valuations are at the higher end for SME space.
Amanta Healthcare IPO concise review
Amanta Healthcare IPO opens on closes on dates
Amanta Healthcare IPO price lot
Quicklinks
- Market Analysis by Nagaraj Shetti
- Stock Market today by Vaishali Parekh
- Analysis by Kotak Securities
- Market Analysis by HDFC Securities
- Technical Analysis by Kotak Securities
- Technical Analysis by Samco Securities
- Reliance, Target & Stoploss
- Gold Analysis
- FII buy-Sell
- Technical Analysis
- Calls for the Day
- Currency Analysis
# This is only coverage of News related to Grey Market Premium & subject to rates. We do not deal in grey market premium. We do not recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
